Avisa Diagnostics Retains Venture Liquidity Providers Inc. for Market-Making Services
May 26, 2021 07:00 ET
|
Avisa Diagnostics Inc.
SANTA FE, N.M., May 26, 2021 (GLOBE NEWSWIRE) -- Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for...
Avisa Diagnostics Begins Trading on the Canadian Securities Exchange
May 18, 2021 07:00 ET
|
Avisa Diagnostics Inc.
Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™Pivotal Trials Planned in...
Avisa Diagnostics Inc. (Formerly, FogChain Corp.) Announces Closing of Reverse Takeover Transaction
May 04, 2021 14:14 ET
|
Avisa Diagnostics Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. SANTA FE, N. M., May 04, 2021 (GLOBE NEWSWIRE) -- Avisa Diagnostics Inc. (formerly, FogChain...
Avisa Reports on Progress with Biomarker AV BreathTest™ Platform
September 18, 2018 08:30 ET
|
Avisa Pharma Inc.
Ten-minute, point-of-care breath test rapidly detects virulent bacterial infections to mitigate overuse of antibiotics and save hospital costsProof-of-concept trial in Emergency Department pneumonia...